ContextProstate cancer is the most common nonskin cancer and second most common
cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically …

Importance There is tremendous interest in using immunotherapy to treat breast cancer, as
evidenced by the more than 290 clinical trials ongoing at the time of this narrative review …

Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector
as a primary vaccination, followed by multiple booster vaccinations employing a …

Purpose Therapeutic prostate-specific antigen (PSA)–targeted poxviral vaccines for prostate
cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for …

Background The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed
death 1 agents has expanded treatment options for patients with locally advanced or …

Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti–
programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic …

Abstract Several anti–PD-1/PD-L1 monoclonal antibodies (mAb) are currently providing
evidence of clinical benefit in subsets of cancer patients. The mode of action of these mAbs …

Purpose: Many patients with clinically localized prostate cancer develop biochemical failure
despite excellent local therapy perhaps due to occult metastatic disease. One potential …

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral
vaccine provided evidence of enhanced median overall survival (OS)(p= 0.0061) in patients …

Background Therapeutic cancer vaccines have shown activity in metastatic castration-
resistant prostate cancer (mCRPC), and methods are being assessed to enhance their …